LB-217

N/A

Report date: 2024/12/10 16:31:28
NME

Base Information

Drug NameLB-217
Drug Alias NameLB-217LB217
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionProbable ATP-dependent RNA helicase DDX53 inhibitors
TargetsProbable ATP-dependent RNA helicase DDX53
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesL-Base Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesL-Base Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A